Can biomarker testing be repeated — on a newer tissue sample?

Yes, in a meaningful number of cases. A biomarker report describes the tumour tissue at the exact moment it was sampled — it is not a fixed, lifelong label. Cancer cells can evolve under the pressure of chemotherapy, radiation, and the disease's own progression, and a marker such as PD-L1 expression can rise, fall, or reappear differently in a newer sample, guided by ASCO and NCCN biomarker-testing standards.

This matters most at progression — when disease has grown or spread after a period of treatment — because that is exactly when tumour biology has had the most opportunity to shift, and when the original report is often oldest relative to what is happening in the body right now.

This page explains why and when retesting is considered, in general terms. It does not, and cannot, interpret your individual report — that conversation belongs with the oncologist who ordered the test and knows your complete clinical picture.

Not automatically — and this is a genuine decision, not a default. A new biopsy is a real procedure with its own risks, discomfort, and practical limits (some sites are hard or unsafe to reach a second time), so your oncologist weighs whether a fresh result would actually open up a different treatment option against the burden of putting you through another sample.

Where a full tissue biopsy isn't practical, a blood-based liquid biopsy can sometimes stand in — it is most established today for tumour mutational burden and certain genetic mutations, and is used case-by-case rather than as a routine replacement for tissue-based PD-L1 testing.

There is no universal rule here. The right answer depends on your cancer type, what specific question is being asked, and what treatment options are actually on the table if the result comes back differently.

This is why the same original PD-L1 report can lead two different patients toward two different decisions on retesting — see how the score itself is read on our page on understanding your PD-L1 score.

1. 1

   Discussing whether a new biopsy is feasible and safe

   Your team weighs the accessible sites, your overall condition, and whether the answer would genuinely change what happens next.

2. 2

   Choosing where the sample comes from

   Where possible, a site that is actively progressing is often preferred over the original tumour location, since it best reflects current biology.

3. 3

   Considering a liquid biopsy alternative

   When tissue is hard or risky to reach, a blood-based test may be discussed for specific markers, depending on your cancer type.

4. 4

   Sending it to an accredited partner lab

   CION coordinates transport and turnaround with accredited partner pathology laboratories; testing itself is not run in-house.

5. 5

   Reviewing the updated report together

   Your oncologist walks through what changed, what stayed the same, and what it does or doesn't mean for your treatment plan.

Tumours are not made of identical cells. Different regions of the same cancer can carry slightly different characteristics — a concept oncologists call tumour heterogeneity — and treatment itself can act as a selection pressure, allowing cells with different biomarker profiles to become more prominent over time. This is a normal, described part of how cancers evolve under treatment, not a sign that anything went wrong with your earlier test.

It is also possible for two labs to report differently on the very same original sample, for technical reasons unrelated to true biological change — a separate issue covered in why two labs gave different PD-L1 results. Before assuming biology has shifted, it is worth ruling out testing-method differences first.

CION coordinates repeat and original biomarker testing alike with accredited partner pathology laboratories, and our oncology team helps you and your family weigh whether retesting is worth it in your specific situation — without pushing a new biopsy that wouldn't change anything. For the fuller picture of how immunotherapy is used and monitored at CION, see Immunotherapy at CION Cancer Clinics.

This page explains repeat biomarker testing in general terms and does not interpret any individual report. Biomarker testing itself is coordinated at accredited partner laboratories, not run in-house. A repeat result, on its own, does not guarantee that your treatment plan will or should change — only your treating oncologist, reviewing your complete case, can advise on eligibility and next steps.

Thousands have navigated progression-stage decisions with us

A report full of numbers can feel like it's deciding everything on its own — especially the second or third time around. Take the first step today; our team walks this part of the journey with you.